Phase 2 N=35 Cabozantinib for Metastatic Triple Negative BrCa
Breast Cancer
Primary: Objective Response Rate — 0.09 proportion of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=103 Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
Lymphoma · Multiple Myeloma and Plasma Cell Neoplasm
Primary: Number of Participants Reporting a Dose Limiting Toxicity (DLT) — 1; 0; 1; 2 participants
Phase 2 N=66 Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis
PBC · Primary Biliary Cirrhosis
Primary: Change From Baseline in Pruritus Using Adult Itch Reported Outcome (ItchRO) Weekly Sum Score at Week 13/ Early Termination (ET) — 48.11; 52.10; 54.64; 49.46 units on a…
Phase 2 N=241 Adding Phosphorus to Osteoporosis Drug Treatment
Osteoporosis · Osteopenia
Primary: Lumbar Spine and Hip BMD, Measured as Grams Per Square Centimeter. — 0.76; 0.78; 0.88; 0.86 g/cm2
Phase 2 N=88 A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia
Acute Myeloid Leukemia · Acute Myelogenous Leukemia
Primary: Kaplan Meier Estimates for One Year Survival — 3.00; 9.61; 13.67 months — p=0.119
Phase 2 N=30 Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate
Atypical Endometrial Hyperplasia · Endometrial Carcinoma
Primary: Best Pathologic Responses — 17; 4; 6; 1 participants
Phase 2 N=161 Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke
Acute Ischemic Stroke
Primary: Change in Infarct Volume From Baseline (Diffusion-Weighted Imaging [DWI]) to Day 5 (Fluid-Attenuated Inversion Recovery [FLAIR]) — 2.17; 2.37 mL — p=0.779
Phase 2 N=159 Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease
Primary: FEV1 AUC 0-12 on Day 7 — 1.452; 1.591; 1.547; 1.539 Liters
Phase 2 N=82 BIIB033 In Acute Optic Neuritis (AON)
Acute Optic Neuritis
Primary: Change in Full-field Visual Evoked Potential (FF-VEP) Latency at Week 24: Intent-to-treat (ITT) Population — 20.83; 17.34 msec — p=0.3337
Phase 2 N=1,002 Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
Dengue Fever
Primary: Geometric Mean Titer (GMT) of Neutralizing Antibodies for Each of the Four Dengue Serotypes Comparing Group D To Groups A and B Combined — 635.04; 181.23; 15104.68…
Phase 2 N=469 Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma
Renal Cell Carcinoma
Primary: Progression Free Survival First-Line (PFS 1-L) — 7.85; 10.71 Months
Phase 2 N=18 Nebulized Hypertonic Saline for Mechanically Ventilated Children
Respiratory Failure
Primary: Duration of Mechanical Ventilation — 129.5; 208.1 hours
Phase 2 N=15 Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia · Recurrent Small Lymphocytic Lymphoma · Refractory Chronic Lymphocytic Leukemia
Primary: Number of Phase I Participants With Dose-Limiting Toxicity Events (Phase I) — 1; 2 Patients reporting Dose-Limiting Events
Phase 2 N=338 Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Clinic Trough Forced Expiratory Volume in One Second (FEV1) at the End of Treatment Phase A (Visit 6/Day 29) — 0.047; 0.146; 0.193; 0.175 Liters…
Phase 2 N=9 rTMS and Retraining in Focal Hand Dystonia
Focal Dystonia
Primary: Change From Baseline in Global Rating of Change at Posttest (Day 5) — 1.3; 1.2 units on a scale